MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Celsion Corporation Net Debt 2011-2025 | CLSN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Celsion Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.73 M | -4.21 M | -5.3 M | -18.8 M | -12.1 M | 9.07 M | 10.3 M | -11.4 M | -63.6 K | 3.88 M | 17.5 M | 36.4 M | -3.29 M | -1.14 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.4 M | -1.14 B | -80.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B |  USA |
 |
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.04 | 4.83 % | $ 235 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
BioVie
BIVI
|
-17.2 M | $ 1.27 | -3.05 % | $ 1.88 M | USA |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 1.17 | 4.46 % | $ 6.38 M |  China |
 |
Aptevo Therapeutics
APVO
|
-3.28 M | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-195 M | $ 212.81 | 1.71 % | $ 5 B |  Danmark |
 |
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.18 | -25.03 % | $ 392 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
-33.1 M | $ 12.37 | 2.06 % | $ 814 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-33.6 M | - | - | $ 7.29 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.1 | 0.16 % | $ 7.46 B |  Australia |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 95.03 | 0.95 % | $ 27.2 B | Germany |
 |
Corcept Therapeutics Incorporated
CORT
|
-121 M | $ 83.59 | 1.95 % | $ 8.63 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
-514 M | $ 24.45 | 0.91 % | $ 2.9 B | USA |
 |
Anika Therapeutics
ANIK
|
-46 M | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
Cortexyme
CRTX
|
-68.6 M | - | -1.05 % | $ 67.1 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
18.3 M | - | - | $ 1.2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
-404 M | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-19.9 M | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
9.86 B | $ 92.45 | 0.34 % | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-24.5 M | $ 26.83 | 0.94 % | $ 1.73 M | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |